Trovagene Enters into Agreement with FedMed, Inc. and Significantly Expands Patient Access to Its Precision Cancer Monitoring Platform

FedMed brings in-network health plan access to an additional 40 million covered lives

SAN DIEGO, Feb. 1, 2016 -- Trovagene, Inc. (TROV), a developer of cell-free molecular diagnostics, announced today that it has entered into an agreement with FedMed, Inc. (FedMed) establishing health benefit access to Trovagene's full line of Precision Cancer Monitoring℠ (PCM) tests and services. Under the agreement, Trovagene's PCM services are covered as a participating laboratory testing provider for clients of FedMed, which include major health insurers such as Aetna, Cigna and Humana, and encompasses over 550,000 in-network physicians nationwide.

Published: 01 February 2016
Written by Editor
Nasdaq   New Product or Order   Up on News  
Read more: Trovagene Inc ( TROV )

Capnia Signs Exclusive Nationwide Distribution Agreement for CoSense®

Capnia and Bemes Enter Collaboration Targeting Hospitals and Physicians

REDWOOD CITY, Calif., Jan. 26, 2016  -- Capnia, Inc. (CAPN), a diversified healthcare company that develops innovative diagnostics, devices and therapeutics addressing unmet medical needs, today announced that it has entered into an exclusive distribution agreement with Bemes, Inc., a leading medical equipment Master Distributor, to market and distribute the CoSense® End-Tidal Carbon Monoxide (ETCO) Monitor and Precision Sampling Sets (PSS).

Under the terms of the agreement, effective January 26, 2016, Bemes will have the exclusive right for sales, marketing, distribution and field service activities for CoSense in the United States.  Bemes and its network of sub distributors will allow comprehensive nationwide distribution of CoSense with 44 sales representatives covering virtually every state. Bemes has placed orders for multiple CoSense monitors, as well as corresponding supplies of PSS in conjunction with the execution of the agreement.

Published: 27 January 2016
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: Capnia Inc ( CAPN )

Trovagene Announces Agreement with America's Choice Provider Network to Offer Patients Access to its ctDNA Precision Cancer Monitoring Platform

Agreement provides in-network coverage for 22 million individuals

SAN DIEGO, Jan. 21, 2016 -- Trovagene, Inc. (TROV), a developer of cell-free molecular diagnostics, announced today that it has entered into an agreement with America's Choice Provider Network (ACPN®) establishing health insurance access to its entire suite of circulating tumor (ct)DNA Precision Cancer Monitoring℠ (PCM) tests and services. Under the terms of the agreement, Trovagene is established as a preferred provider, and its PCM testing services will be covered by over 1,700 payers in North America.

Published: 21 January 2016
Written by Editor
Nasdaq   New Product or Order   Up on News  
Read more: Trovagene Inc ( TROV )

Biocept Announces In-Network Agreement with Blue Cross Blue Shield of Illinois

More than eight million members gain access to Biocept's suite of blood-based diagnostics through agreement with Illinois' largest health plan, bringing total covered lives to approximately 133 million

SAN DIEGO, Jan. 12, 2016 -- Biocept, Inc. (BIOC), a molecular diagnostics company commercializing and developing blood-based biomarkers to improve the detection and treatment of cancer, announces that it has entered into an agreement with Blue Cross Blue Shield of Illinois (BCBS IL) allowing its members access to Biocept's broad menu for liquid biopsy testing.  With the addition of BCBS IL's more than eight million members, the number of patients with access to Biocept's liquid biopsy assays through their healthcare insurance plan has increased to approximately 133 million.

Published: 12 January 2016
Written by Editor
Nasdaq   New Product or Order   Up on News  
Read more: Biocept Inc ( BIOC )

Biocept Launches Blood-based Test for Prostate Cancer and Expands Offering in Breast Cancer

Introduction of blood-based assay to detect androgen receptor expression builds on leading position in detecting and monitoring cancer through liquid biopsy

SAN DIEGO, Jan. 7, 2016 -- Biocept, Inc. (BIOC), a molecular diagnostics company commercializing and developing biomarkers to improve the detection and treatment of cancer, announces the launch of the CLIA-validated androgen receptor expression assay using a patient's blood for the detection and monitoring of late-stage prostate cancer and a certain form of breast cancer.

Published: 07 January 2016
Written by Editor
Nasdaq   New Product or Order   Up on News  
Read more: Biocept Inc ( BIOC )
  1. Aeterna Zentaris Inc ( AEZ / AEZS )
  2. Genetic Technologies Limited ( GENE )
  3. Cancer Genetics Inc ( CGIX )
  4. Spectral Medical Inc ( EDT )
  5. Digirad Corporation ( DRAD )